Literature DB >> 17728174

Trypanosoma cruzi infection from the view of CD8+ T cell immunity--an infection model for developing T cell vaccine.

Yasushi Miyahira1.   

Abstract

Chagas' disease is caused by Trypanosoma cruzi (T. cruzi) which was once prevalent in Central and South America. Although the recent success in Triatoma vector control has made the disease being possibly "extinct" in the near future, the development of effective preventive and therapeutic vaccines is still necessary to prevent the resurgence of the neglected infection. In addition to the importance for containing the disease, T. cruzi infection presents unique features for elucidating hosts' immune responses against intracellular infectious agents. Due to its biological capacity for invading into principally any types of cells and for causing systemic infection which damages particularly muscle and neural cells, T cell immunity is critical for resolving its infection. Although T cell-mediated immune responses have been, so far, extensively investigated in viral and bacterial infections, parasitic infection such as malaria has presented epoch-making discovery in T cell immunity. Recent advances in the analyses of T cell-mediated immune responses against T. cruzi infection now make this infectious disease potentially more suitable for detecting subtle immunological changes in hosts' immune defense upon modifying immune system. The current review focuses on the usefulness of T. cruzi infection as a model for developing effective CD8(+) T cell-mediated vaccine against intracellular infectious agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17728174     DOI: 10.1016/j.parint.2007.07.005

Source DB:  PubMed          Journal:  Parasitol Int        ISSN: 1383-5769            Impact factor:   2.230


  15 in total

1.  CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance.

Authors:  Charles S Rosenberg; Dianya L Martin; Rick L Tarleton
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

2.  NADPH oxidase inhibition ameliorates Trypanosoma cruzi-induced myocarditis during Chagas disease.

Authors:  Monisha Dhiman; Nisha Jain Garg
Journal:  J Pathol       Date:  2011-09-26       Impact factor: 7.996

3.  Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection.

Authors:  Eiji Takayama; Takeshi Ono; Elena Carnero; Saori Umemoto; Yoko Yamaguchi; Atsuhiro Kanayama; Takemi Oguma; Yasuhiro Takashima; Takushi Tadakuma; Adolfo García-Sastre; Yasushi Miyahira
Journal:  Int J Parasitol       Date:  2010-07-08       Impact factor: 3.981

Review 4.  Immunity and immune modulation in Trypanosoma cruzi infection.

Authors:  Fabíola Cardillo; Rosa Teixeira de Pinho; Paulo Renato Zuquim Antas; José Mengel
Journal:  Pathog Dis       Date:  2015-10-04       Impact factor: 3.166

5.  Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge.

Authors:  Matthew H Collins; Julie M Craft; Juan M Bustamante; Rick L Tarleton
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

6.  Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.

Authors:  Eduardo L V Silveira; Carla Claser; Filipe A B Haolla; Luiz G Zanella; Mauricio M Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

7.  Subdominant/cryptic CD8 T cell epitopes contribute to resistance against experimental infection with a human protozoan parasite.

Authors:  Mariana R Dominguez; Eduardo L V Silveira; José Ronnie C de Vasconcelos; Bruna C G de Alencar; Alexandre V Machado; Oscar Bruna-Romero; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

8.  Differential phenotypic and functional profiles of TcCA-2 -specific cytotoxic CD8+ T cells in the asymptomatic versus cardiac phase in Chagasic patients.

Authors:  Adriana Egui; M Carmen Thomas; Bartolomé Carrilero; Manuel Segovia; Carlos Alonso; Concepción Marañón; Manuel Carlos López
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

9.  Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection.

Authors:  Rafael Polidoro Alves Barbosa; Bruno Galvão Filho; Luara Isabela Dos Santos; Policarpo Ademar Sales Junior; Pedro Elias Marques; Rafaela Vaz Sousa Pereira; Denise Carmona Cara; Oscar Bruña-Romero; Maurício Martins Rodrigues; Ricardo Tostes Gazzinelli; Alexandre Vieira Machado
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

10.  Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi.

Authors:  Raquel Tayar Nogueira; Alanderson Rocha Nogueira; Mirian Claudia Souza Pereira; Maurício Martins Rodrigues; Patrícia Cristina da Costa Neves; Ricardo Galler; Myrna Cristina Bonaldo
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.